• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Internal Iliac Artery Balloon Occlusion for Placenta Previa Management

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Yu et al. (AJOG, 2020) assessed whether internal iliac artery balloon occlusion during cesarean delivery for placenta previa reduces postpartum hemorrhage (PPH) and other complications

METHODS:

  • Prospective randomized controlled trial (RCT)
  • Participants
    • Confirmed placenta previa at 32 to 34 weeks following identification of low-lying placenta at 18 to 22 weeks ultrasound | Scheduled for cesarean delivery
    • Placenta previa definition:  Lower placenta edge within 2cm from the internal os
  • Interventions
    • Internal iliac artery balloon occlusion (Occlusion)
      • Balloon catheter placed in internal iliac arteries and inflated following delivery  
    • Standard management (Control)
  • Primary outcome
    • PPH Reduction
  • Secondary outcomes
    • Hemoglobin drop after delivery | Amount of blood product transfusion
    • Incidence of hysterectomy
    • Maternal complications: Renal failure | DIC | ARDS
    • Length of stay | NICU admission
    • Maternal death
  • Statistical analysis – Power calculation
    • Average blood loss in typical cesarean with previa: 800 to 1000 mL
    • 80% Power | Significance level of 5% | Ability to detect a 400 mL blood loss difference
    • 10 subjects needed in each arm (increased to allow for drop out)

RESULTS:

  • 40 women were randomized | 20 to each group
    • Demographic and obstetric characteristics were similar between the two groups
  • In the occlusion group, 4 women did not receive the scheduled procedure
    • Antepartum hemorrhage and emergency cesarean: 3 patients  
    • Resolution of placenta previa at 36 weeks (edge of placenta >2cm from internal os)
  • An intention-to-treat analysis found no significant differences for the following
    • Median intra-operative blood loss (p=0.945)
    • Median length of surgery (p=0.204)
    • Need for blood transfusion during operation (p=0.621)
  • None of the patients experienced
    • Rebleeding after operation
    • Complication related to baloon procedure
    • Any other maternal complications
  • A re-analysis of the data using an on-treatment approach showed the same results

CONCLUSION:

  • Internal iliac artery balloon occlusion did not demonstrate benefit for reduction of PPH or other perinatal complications for placenta previa

Learn More – Primary Sources:

Perioperative prophylactic internal iliac artery balloon occlusion in the prevention of postpartum hemorrhage in placenta previa: a randomized controlled trial.

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Placenta Previa – Nomenclature, Diagnosis and Clinical Management
How Effective is Intrauterine Balloon Tamponade for Severe Postpartum Hemorrhage
Does Time of Day Impact Ordering and Completion of Breast and Colon Cancer Screening Tests?
Does Prophylactic TXA Reduce Postpartum Hemorrhage?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site